DRUG STUDY: NCM 106 PHARMACOLOGY Instructor: _______________________________________ Date: ________________________

NAME: ____________________________________________________________ BLOCK and Year:___________________________Group: ______________________________

DRUG NAME MECHANISM OF INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING INTERVENTIONS

ACTION
Generic Name: Exerts antiviral effect CMV retinitis in AIDS  Hypersensitivity to drug,  CNS: headache, seizures, Patient monitoring:
cidofovir by interfering with patients probenecid, or other sulfa- coma  Assess white blood cell
DNA synthesis of containing agents  EENT: decreased count and creatinine and
CMV, thereby  Creatininelevelabove1.5mg/ intraocular pressure urine protein levels
inhibiting viral dl, calculated creatinine  GI: nausea, vomiting, within 48 hours of each
replication diarrhea, anorexia, oral dose.
clearance of 55 ml/ minute
candidiasis
Drug Classification: or less, or urine protein  Closely monitor
 GU: proteinuria,
Antiviral level of 100 mg/dl or higher nephrotoxicity intraocular pressure and
 Concurrent use of Hematologic: neutropenia visual acuity.
nephrotoxic drugs  Hepatic: hepatomegaly  Monitor hepatic enzyme
 Metabolic: metabolic levels in patients with
acidosis hepatic disease.
 Musculoskeletal: muscle
contractions Patient teaching:
Available Dosage:  Respiratory: dyspnea,  Tell patient to
CMV retinitis in increased cough immediately report
AIDS patients  Skin: rash, alopecia fever, vision
Adults: 5 mg/kg I.V.  Other: pain, fever, chills, changes, nausea,
infused over 1 hour infection, pain at I.V. site vomiting, rash, or
q week for 2 urinary output
continuous weeks; changes.
then 5 mg/kg I.V.  Instruct patient to
once q 2 weeks as a take probenecid, as
maintenance dose prescribed, before
each dose and to
have regular eye
examinations.
 Urge female patient
of childbearing age
to use effective
contraception during
and for 1 month after
 therapy.
 Instruct male
patients to use
barrier contraception
during and for 3
months after therapy.
 As appropriate,
review all other
significant and life-
threatening adverse
reactions and
interactions,
especially those
related to the drugs
and tests mentioned
above.